Pressure mounts to stop state, federal coverage for ED drugs
The Alabama Medicaid Agency said last week it will no longer approve phosphodiesterase type-5 inhibitors for erectile dysfunction.
The Alabama Medicaid Agency said last week it will no longer approve phosphodiesterase type-5 inhibitors for erectile dysfunction. The drugs will be approved only for patients who have severe pulmonary hypertension.
The agency's action follows its recent decision to deny coverage of PDE-5 inhibitors to registered sex offenders.
"Even though it was a relatively small amount of money, this is not where we want to be," Alabama Medicaid spokesperson Mary Finch told the Montgomery Advertiser.
Meanwhile, at the federal level, Rep. Nathan Deal (R-GA) said he would draft legislation to remove erectile dysfunction drugs from Medicare and Medicaid coverage, according to an Associated Press report. Deal is chairman of a health subcommittee that is looking at ways to save money in the Medicaid program.
States are allowed to define what is "medically necessary," and some states, including Texas, have already determined PDE-5 inhibitors are not, Deal said.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Dr. Goudelocke outlines stand-up urgency in patients with OAB
April 18th 2024"There are plenty of articles written about stress-induced urgency. I, at the time, only found 1 article written in the gynecologic literature about what they called stand-up urgency," according to Colin Goudelocke, MD.
